Argenica Therapeutics (ASX: $AGN) Phase 2 Stroke Trial Commencement

Argenica Therapeutics Limited (ASX: $AGN) has successfully dosed the first acute ischaemic stroke (AIS) patient in its Phase 2 clinical trial of ARG-007. The patient, enrolled at the Royal Melbourne Hospital, met the eligibility criteria for mechanical thrombectomy and had a confirmed diagnosis of acute ischaemic stroke caused by a large vessel occlusion (LVO). Three of the ten hospital sites are now activated to begin patient dosing, with the first assessment of patient safety to be conducted by the Data Safety Monitoring Board following dosing of the first five patients.

Executive Commentary on Phase 2 Stroke Trial Commencement

We are absolutely delighted to have officially commenced our Phase 2 clinical trial by dosing our first stroke patient. We will be carefully monitoring the recruitment of patients in this trial, and report progress as we go. We have engaged an amazing clinical trial team in hospital stroke units across Australia and are looking forward to continuing to work with them throughout the trial.

Summary of Phase 2 Stroke Trial Commencement

Argenica Therapeutics (ASX: $AGN) has initiated the Phase 2 clinical trial of ARG-007, successfully dosing the first AIS patient. The trial aims to determine the safety, preliminary efficacy, and pharmacokinetics of ARG-007 in AIS patients, with the potential to progress to a pivotal Phase 3 trial. Additionally, the trial seeks to generate preliminary data on the neuroprotective ability of ARG-007 in reducing brain tissue death following stroke and mechanical clot removal. By focusing on LVO stroke patients eligible for endovascular thrombectomy, the trial aims to improve patient outcomes and address the devastating impact of LVO strokes. Argenica's engagement with hospital stroke units across Australia demonstrates its commitment to advancing neuroprotective clinical validation and improving patient care in neurological conditions.